Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
2017
The recently reported ANTARCTIC trial by Cayla and colleagues is the latest large-scale study of personalized antiplatelet therapy based on platelet function testing (1). In this open-label, blinded end-point, randomized, controlled trial, the authors ascertained the net clinical benefit of individualized antiplatelet therapy based on platelet function monitoring in elderly patients undergoing stenting (PCI) for an acute coronary syndrome (ACS).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI